Axa’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Axa’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-14,060	Closed	-$239K	–	1369
2019 Q2	$239K	Buy	14,060 +10,490	+294%	+$284K	﹤0.01%	1202
2019 Q1	$120K	Hold	3,570	–	–	﹤0.01%	1291
2018 Q4	$104K	Hold	3,570	–	–	﹤0.01%	1274
2018 Q3	$220K	Hold	3,570	–	–	﹤0.01%	1284
2018 Q2	$263K	Buy	+3,570	New	+$278K	﹤0.01%	1260

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Axa's BLCM Position: Q3 2019 in Review

Axa sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2019, closing a stake of 14,060 shares — an estimated $239K sold.

Axa first reported a position in BLCM in Q2 2018 and held it in 5 quarters. The position peaked at $263K in Q2 2018. 67 funds tracked by Wall St. Rank hold BLCM as of Q3 2019.

Axa reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Axa sold 14,060 Bellicum Pharmaceuticals, Inc. shares in Q3 2019, an estimated $239K.
Axa first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2018 and held it in 5 quarters.
Axa's Bellicum Pharmaceuticals, Inc. position peaked at $263K in Q2 2018.
67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2019.

Based on Axa's 13F filing for Q3 2019, filed 14 Nov 2019.